创伤性脑损伤患者中不适当抗血栓药物处方的患病率与预测因素
该回顾性研究分析了2016年1月至2020年9月在一级创伤中心就诊的141例伤前使用抗血栓药物的创伤性脑损伤患者,发现总体不适当抗血栓药物使用率为1/10,静脉血栓栓塞症适应证的不适当率最高,年龄和女性是预测因素。
要点
- 创伤性脑损伤患者中约1/10伤前抗血栓药物使用不适当。
- 静脉血栓栓塞症适应证的不适当抗血栓药物使用率最高。
- 年龄小于65岁和大于85岁以及女性是不适当抗血栓药物使用的预测因素。
核心结论
- 总体而言,每10例就诊的创伤性脑损伤患者中就有1例被发现正在使用不适当的抗血栓药物。
研究设计与样本
- 回顾性病历审查,纳入2016年1月至2020年9月期间在一级创伤中心就诊的所有创伤性脑损伤且伤前使用抗血栓药物的患者,共141例。
主要发现
- 141例患者中,女性占41.8%(n=59),平均年龄80.6±9.9岁。
- 处方抗血栓药物包括阿司匹林25.5%(n=36)、氯吡格雷22.7%(n=32)、华法林46.8%(n=66)、达比加群2.1%(n=3)、利伐沙班10.6%(n=15)、阿哌沙班18.4%(n=26)。
- 抗血栓药物适应证为心房颤动66.7%(n=94)、静脉血栓栓塞症13.4%(n=19)、心脏支架8.5%(n=12)、心肌梗死/残余冠状动脉疾病11.3%(n=16)。
- 不适当抗血栓药物使用率随适应证不同而显著变化(P<.001),静脉血栓栓塞症最高。
- 预测因素包括年龄(P=.005),小于65岁和大于85岁比例更高,以及女性(P=.049);种族和抗血栓药物种类不是显著预测因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: A growing proportion of the US population is on antithrombotic therapy (AT), most significantly within the older subpopulation. Decision to use AT is a balance between the intended benefits and known bleeding risk, especially after traumatic brain injury (TBI). Preinjury inappropriate AT offers no benefit for the patient and also increases the risk of intracranial hemorrhage and worse outcome in the setting of TBI. Our objective was to examine the prevalence and predictors of inappropriate AT among patients presenting with TBI to a Level-1 Trauma Center. METHODS: A retrospective chart review was performed on all patients with TBI and preinjury AT who presented to our institution between January 2016 and September 2020. Demographic and clinical data were collected. Appropriateness of AT was determined through established clinical guidelines. Clinical predictors were determined by logistic regression. RESULTS: Of 141 included patients, 41.8% were female (n = 59) and the average age (mean ± SD) was 80.6 ± 9.9. The prescribed antithrombotic agents included aspirin (25.5%, n = 36), clopidogrel (22.7%, n = 32), warfarin (46.8%, n = 66), dabigatran (2.1%, n = 3), rivaroxaban (Janssen) (10.6%, n = 15), and apixaban (Bristol-Myers Squibb Co.) (18.4%, n = 26). The indications for AT were atrial fibrillation (66.7%, n = 94), venous thromboembolism (13.4%, n = 19), cardiac stent (8.5%, n = 12), and myocardial infarction/residual coronary disease (11.3%, n = 16). Inappropriate antithrombotic therapy use varied significantly by antithrombotic indication ( P < .001) with the highest rates seen with venous thromboembolism. Predictive factors also include age ( P = .005) with higher rates younger than 65 years and older than 85 years and female sex ( P = .049). Race and antithrombotic agent were not significant predictors. CONCLUSION: Overall, 1 in 10 patients presenting with TBI were found to be on inappropriate AT. Our study is the first to describe this problem and warrants investigation into possible workflow interventions to prevent post-TBI continuation of inappropriate AT.
引用
- Blitz SE, Mashouf LA, Nieves A, et al. Prevalence and Predictors of Inappropriate Antithrombotic Prescription in Patients Presenting With Traumatic Brain Injury. Neurosurgery. 2023. PMID: 37235974. doi:10.1227/neu.0000000000002540
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。